3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
COVID-19
1
Interventions
Temozolomide
107
Radiotherapy
60
Radiation
28
Bevacizumab
19
Magnetic Resonance Spectroscopy
16
Nivolumab
15
Surgical Procedures, Operative
12
Irinotecan
11
Cyclophosphamide
10
Specimen Handling
9
Chemotherapy, Adjuvant
9
Radiotherapy, Intensity-Modulated
8
Radiosurgery
8
O(6)-benzylguanine
8
Carmustine
8
poly ICLC
7
pembrolizumab
7
motexafin gadolinium
7
fludarabine
7
Leukapheresis
7
Flucytosine
7
sargramostim
6
Radiotherapy, Conformal
6
Erlotinib Hydrochloride
6
Lomustine
5
Ipilimumab
5
Imiquimod
5
Imatinib Mesylate
5
Hydroxyurea
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Glioblastoma
×
bemcentinib
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts